DEALS: GSK, ChemoCentryx ink $1.5B pact


GSK, ChemoCentryx ink $1.5B pact


DEALS

WHO

WITH

WHAT

SCOOP

GlaxoSmithKline

ChemoCentryx

$1.5B collaboration pact

The deal revolves around developing new therapies from chemokine and chemoattractant receptors for inflammatory diseases.

Mylan Laboratories

Matrix Laboratories

$735 million acquisition

In a move to expand its reach around the globe, Mylan Laboratories has acquired a majority interest in India's Matrix Laboratories.

Infinity Pharmaceuticals

MedImmune

$500M development deal

Infinity Pharmaceuticals and MedImmune will advance new therapies for blood-related cancers and solid tumors.

Dishman Pharmaceuticals and Chemicals

Carbogen Amcis

$75M purchase

Carbogen Amcis controls three production facilities. Dishman says it expects to be able to improve margins at the contract manufacturing operation.

Dyax

Paul Capital Partners

$30M payment

Dyax receives the payment from Paul Capital Partners in exchange for a portion of the revenue generated by its Phage Display Licensing and Funded Research Program.

Isolagen

Agera Laboratories

$2.67M deal

Agera Laboratories makes clinically developed skincare products.

Orthodontix

Protalix

Merger

Once the merger is complete a small group of investors will invest $15 million in Protalix in exchange for 14 percent of the company.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.